Recent Updates
Recently added Catalysts

GX-03

Phase 2

Covid19 | Small molecule | Infectious Disease |Turn Therapeutics Inc.|Last Updated: May 18, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment85
FDA Designations
No designations recorded
Clinical trial landscape

GX-03 · 2 trials · 4 indications

Phase 2 2
NCT07355075A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)Eczema Atopic Dermatitis
RECRUITING110 Analytics
NCT04951349Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.Covid19
COMPLETED85 Analytics
PHASE2RECRUITING
A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
Eczema Atopic Dermatitis
NCT07355075110
Unlock trial analytics
PHASE2COMPLETED
Safety and Efficacy of Intranasal Application of GX-03 as a Treatment and Prevention for COVID-19.
Covid19
NCT0495134985
Unlock trial analytics
Study Endpoints
Primary Endpoints
Change in Investigator Global Assessment (IGA) at Week 8
At Day 56 (Week 8)

vIGA-AD score of 0 (clear) or 1 (almost clear) with a ≥2-grade improvement from baseline at Week 8

Reduction of 60% in viral load from baseline
5 days

Time to achieve a 60% reduction in viral load from baseline.

Primary Safety analysis
5-10 days

To evaluate the incidence rate(s) of non-serious and serious adverse events associated with administration of the study product.

Secondary Endpoints
Change in Baseline Eczema Area and Severity (EASI) at Week 8
At Day 56 (Week 8)
≥4 Point reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) at Week 8
At Day 56 (Week 8)
Patient-Oriented Eczema Measure (POEM) score at Week 8
At Day 56 (Week 8)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
GX-03EXPERIMENTALTreatment Arm
VehicleEXPERIMENTALVehicle Control
Treatment of hospitalized patients with laboratory-confirmed COVID-19EXPERIMENTALHospitalized patients with laboratory-confirmed COVID-19 using GX-03 administered intranasally TID for 5 days.
Placebo Treatment of hospitalized patients with laboratory-confirmed COVID-19PLACEBO_COMPARATORHospitalized patients with laboratory-confirmed COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 5 days.
Prevention of SARS-COV-2 in Health Care ProvidersEXPERIMENTALHealth care providers with laboratory-confirmed negative COVID-19 using GX-03 administered intranasally TID for 10 days.
Placebo Prevention of SARS-COV-2 in Health Care ProvidersPLACEBO_COMPARATORHealth care providers with laboratory-confirmed negative COVID-19 using placebo (petrolatum emulsion) administered intranasally TID for 10 days.
Interventions
NameTypeDescription
GX-03COMBINATION_PRODUCTTopical ointment
VehicleOTHEROintment carrier
Petrolatum ointmentDRUGViscous ointment similar in form to study drug.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites1

Participants must meet all of the following criteria: * Adults aged 18 to 80 years, inclusive * Male or female subjects in good general health as determined by medical history * Presence of visible eczematous skin with disease severity consistent with moderate to severe eczema, as assessed by: * Ec...

Countries:United StatesPanama
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMMay 26, 2026NCT07355075Enrollment: 100 → 110
LOWMay 24, 2026NCT07355075studyFirstPostDate: changed